EP3883889A1 - Behandlung von hautkrankheiten auf der basis von elektrolysiertem wasser - Google Patents

Behandlung von hautkrankheiten auf der basis von elektrolysiertem wasser

Info

Publication number
EP3883889A1
EP3883889A1 EP19813431.4A EP19813431A EP3883889A1 EP 3883889 A1 EP3883889 A1 EP 3883889A1 EP 19813431 A EP19813431 A EP 19813431A EP 3883889 A1 EP3883889 A1 EP 3883889A1
Authority
EP
European Patent Office
Prior art keywords
water
electrolysis
treatment
ppm
mah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19813431.4A
Other languages
English (en)
French (fr)
Inventor
Anthony Ginter
Laurent Pupunat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Weo LLC
Original Assignee
Waterdiam Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waterdiam Group LLC filed Critical Waterdiam Group LLC
Publication of EP3883889A1 publication Critical patent/EP3883889A1/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/46Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/467Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction
    • C02F1/4672Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation
    • C02F1/4674Treatment of water, waste water, or sewage by electrochemical methods by electrolysis by electrochemical disinfection; by electrooxydation or by electroreduction by electrooxydation with halogen or compound of halogens, e.g. chlorine, bromine
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/46Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F1/00Treatment of water, waste water, or sewage
    • C02F1/46Treatment of water, waste water, or sewage by electrochemical methods
    • C02F1/461Treatment of water, waste water, or sewage by electrochemical methods by electrolysis
    • C02F1/46104Devices therefor; Their operating or servicing
    • C02F1/46109Electrodes
    • C02F2001/46133Electrodes characterised by the material
    • C02F2001/46138Electrodes comprising a substrate and a coating
    • C02F2001/46147Diamond coating
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/02Non-contaminated water, e.g. for industrial water supply
    • C02F2103/026Treating water for medical or cosmetic purposes
    • CCHEMISTRY; METALLURGY
    • C02TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02FTREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
    • C02F2103/00Nature of the water, waste water, sewage or sludge to be treated
    • C02F2103/42Nature of the water, waste water, sewage or sludge to be treated from bathing facilities, e.g. swimming pools

Definitions

  • the invention relates to the field of treatment of skin conditions such as eczema or atopic dermatitis.
  • the invention relates more particularly to a process for obtaining water useful for the treatment of skin conditions comprising an electrolysis treatment.
  • the invention also relates to the water obtained by this process, its use for the treatment of said skin conditions by direct application or in the form of compositions, and a suitable device for treating said conditions.
  • Eczema which is defined as an inflammation of the skin.
  • Eczemas because there are several types, can be allergic or contact or nummular in nature in the form of isolated patches of irritated skin located most often on the arms, buttocks, back or lower legs.
  • Atopic dermatitis is a pruritic and inflammatory dermatosis that can be accompanied by asthma, which can spread all over the body in the form of large plaques.
  • W0200710766 is cited without being exhaustive.
  • the subject of the invention is the use of E-3- [3- [N- (4-methoxybenzenesulfonyl) -N- isopropylamino] phenyl] -3- (3-pyridyl) propenohydroxamic acid of formula (I); or of a pharmaceutically acceptable salt thereof, pharmaceutically acceptable solvents or hydrates, for the preparation of a medicament intended for preventing and / or treating inflammatory skin pathologies, as well as pharmaceutical compositions, in particular dermatological compositions, comprising acid E -3- [3- [N- (4-methoxybenzenesulfonyl) -N-isopropylamino] phenyl-3- (3-pyridyl)
  • propenohydroxamic or a pharmaceutically acceptable salt thereof, pharmaceutically acceptable solvents or hydrates, for the treatment and / or prevention of inflammatory skin diseases.
  • WO2018041751 which relates to a sulfated polysaccharide extracted from a red alga of the species Haliptilon subulatum, or a salt thereof as an active principle. More particularly, it relates to a sulfated polysaccharide extracted from a red alga of the species Haliptilon subulatum, or a salt thereof as an active principle, for its use in the modulation of the immune response in humans. human or animal, in particular in the prevention and / or treatment of inflammatory diseases, in particular in the skin.
  • One of the aims of the invention is therefore to remedy the aforementioned drawbacks and to meet the aforementioned needs by providing electrolyzed water for use in the treatment of inflammatory skin diseases.
  • the envisaged use of the electrolyzed water according to the invention is done in the treatment of eczema or atopic dermatitis.
  • the electrolyzed water according to the invention is obtained by the implementation of a three-step process which begins with the use of running water or spring water optionally added with sodium chloride (NaCl) at the concentration 0, 5 to 2g / L followed by electrolysis of said water by an electrolysis module comprising at least one diamond electrode doped with boron fixed on silicon substrate in which the boron concentration is between 200 ppm (3x10 19 B atoms / cm 3 ) and 2000 ppm (3.52x10 20 B atoms / cm 3 ), in particular between 200 ppm (3x10 19 B atoms / cm 3 ) and 1500 ppm (2x10 20 B atoms / cm 3 ), the said module submitting the water at an amount of current (current density) during the electrolysis process between 15 and 500 mAh / L of water, more preferably 40 to 250 mAh / L of water, even more preferably 50 to 200 mAh / L, the duration of the electrolysis being less than or equal to 60 minutes and in particular between 15 and
  • the electrolysis can be carried out in one continuous or cyclic manner during which the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour.
  • the invention also relates to electrolyzed water obtained by the process described above.
  • the invention also relates to a composition comprising an electrolyzed water according to the invention for use as a medicament in the treatment of inflammatory skin diseases.
  • the treatment of inflammatory diseases with this composition relates to eczema or atopic dermatitis.
  • composition comprising electrolyzed water according to the invention, mainly composed and all or part of water, it consists of 95 to 100% of electrolyzed water and 0 to 5% of an excipient and / or emulsifier.
  • composition according to the invention may be in the form of a cream, a gel, a dressing, a patch.
  • composition according to the invention for treating skin conditions can consist of a mask that can be applied to the skin or the face, said mask being obtained from a powder such as a clay, an exfoliant, a plant extract in powder or a clay containing activated carbon and added with electrolyzed water obtained according to the process described above.
  • composition according to the invention when exclusively composed of electrolyzed water, this can be added to a device containing it.
  • Said device being a swimming pool, a spa, a bathtub or a shower.
  • the electrolyzed water according to the invention for use in the treatment of inflammatory skin diseases is used over a period ranging from 5 to 60 minutes of exposure.
  • the electrolyzed water is obtained thanks to an electrolysis module allowing the implementation of the method described above, said module being if necessary present in a fixed or mobile manner in a device such as a swimming pool, a spa, a bathtub or a shower.
  • Figure 1 shows a portion of the ankle of a child suffering from eczema before applying water according to the invention
  • Figure 2 shows the ankle portion of Figure 1 five hours after applying the water according to the invention
  • Figure 3 shows the ankle portion of Figure 1 two days after applying the water according to the invention
  • Figures 1 to 3 show the effectiveness of the electrolyzed water according to the invention in the treatment of eczema on the skin of the feet of a child before treatment and after treatment by bathing in electrolysed water.
  • Figure 4 represents the action of a composition according to the invention comprising an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes A, 1200 ppm of boron) on silicon substrate on the healing process a wound.
  • a composition according to the invention comprising an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes A, 1200 ppm of boron) on silicon substrate on the healing process a wound.
  • Figure 5 shows a comparative test between a treatment with conventional water (control) and electrolyzed water in a composition according to the invention on the healing process.
  • FIG. 6 represents the action of an electrolyzed water obtained by electrolysis of water by diamond electrodes doped with boron (Electrodes B, 2500 ppm of boron) on silicon substrate on the healing process of a wound.
  • Eczema is a pruritic dermatosis that manifests itself by a non-contagious inflammation of the skin which is accompanied by redness, fine vesicles, dander and itching. People who have it experience periods when the disease manifests as flares during which symptoms worsen and then subside. These episodes of relapse and lull or remission spread over a more or less long period, especially in adolescents, which can be very disturbing in adolescents.
  • the aesthetics of eczema can range from bright red patches spread over a more or less significant part of the body, or appear in the form of pimples. purulent and irritating localized on the face or arms or legs. Beyond the unsightly aspect of these manifestations and the discomfort which results from them, there is pain.
  • eczema Among all skin diseases, eczema is the most common: this disease motivates up to 30% of dermatology consultations, reaching 15% to 30% of children and 2% to 10% of adults. Eczema cases have doubled or even tripled in the past 30 years.
  • contact or allergic dermatitis which are characterized by lesions of eczema after contact of the skin with certain substances called allergens which can be chemical substances, clothes, sometimes metals.
  • allergens can be chemical substances, clothes, sometimes metals.
  • Eczema can appear after a few minutes or 3 to 10 days depending on the degree and time of exposure to the allergen.
  • the allergic reaction can appear very early in the subject or much later in his life,
  • atopic dermatitis characterized by allergic reactions mediated by antibodies called IgE in contact with allergens normally harmless to the rest of the population (dust, pollen, animal hair, etc.).
  • allergens normally harmless to the rest of the population (dust, pollen, animal hair, etc.).
  • Atopic people often present, simultaneously or alternately, various allergic reactions, such as hay fever, hives, asthma or food allergies.
  • lesions appear on the cheeks, forehead and scalp until they extend to the extension faces of the arms and legs and the trunk. They are characterized by dry and rough or oozing and crusty redness, which has the disadvantage of itching and irritation because often lesions of atopic dermatitis will predominate in the bending folds of the elbows and knees or even wrists.
  • the lesions are located mainly on the face, neck and limbs. They are often thickened and sometimes purulent.
  • Creams or ointments based on corticosteroids are applied to the areas to be treated, which reduces itching and inflammation. Creams and ointments that have a strong steroid effect are used to relieve significant irritation, but over a short period, because in the long term, they lose their effectiveness and can thin the skin.
  • Antihistamines are also used against itching, but their action time is limited in time and requires several doses.
  • Immunomodulatory drugs are also a remedy against the use of corticosteroids and have the effect of decreasing the activity of the immune system (therefore inflammation) with more or less side effects.
  • drugs like Tacrolimus or Pimecrolimus.
  • Cyclosporine may be considered. Cyclosporine is an agent of fungal origin which has immunomodulatory properties, it is not devoid of significant side effects on the liver or blood pressure, it can only be used for short periods.
  • the present invention concerning a particular electrolyzed water obtained by a process involving particular electrodes of diamond doped with boron fixed on silicon makes it possible to solve the problems or drawbacks previously mentioned. It has the following advantages and improvements:
  • the electrolysis module for implementing the method according to the invention in order to prepare the electrolyzed water useful for the treatment of inflammatory skin diseases comprises at least one, preferably at least two boron-doped diamond electrodes which are fixed on a silicon substrate.
  • each electrode is between 10 and 100 cm 2 , preferably 60 and 80, more preferably around 70 cm 2 .
  • the boron doping of the diamond electrode also has its importance on the properties of the water obtained; the boron concentration is in particular between 200 ppm (3 ⁇ 10 19 B atoms / cm 3 ) and 1500 ppm (2 ⁇ 10 20 B atoms / cm 3 ).
  • This boron concentration as well as the nature of the diamond-based electrodes on silicon gives it properties allowing it to operate on a potential between -1V and -2V on the cathodic polarization and on + 2V and + 4V on the anodic polarization. comparison to a platinum reference electrode.
  • the electrolysis module is connected to a power supply module and is open to a flow of water which will pass through it.
  • the electrodes are supplied with direct current by the power supply module which is connected to the electrolysis module supplying a direct current to said electrode, generally this is fixed between 1 , 5A and 3A. If reverse polarity is required, this can be done automatically by the power module.
  • Water can come from different sources but must pass through the electrolysis module without it being able to function in the absence of water.
  • the electrolysis module can be permanently traversed by water depending on the device in which it is located.
  • An internal measurement or hydraulic flow sensor system is present, interacting with the supply module and which allows the standby, shutdown or start-up of the electrolysis module in the absence or presence of water and therefore to activate electrolysis.
  • the water electrolysis module according to the present invention can advantageously operate in automatic mode or can be activated or deactivated on demand, manually or using a remote control system.
  • Another advantage of the present invention lies in the fact that the water electrolysis module does not necessarily need permanent activation, but can be usefully activated periodically, that is to say at convenient intervals. , preferably but not necessarily at regular intervals. It has been found that electrolysis of water at regular intervals allows the water to remain therapeutically active for a long time.
  • Activating the electrolysis module in order to subject the water to cyclic electrolysis and in which the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour allows '' obtain water with therapeutic potential.
  • the electrolysis module allows the implementation of the process for the preparation of electrolyzed water according to the invention, characterized by the implementation of the following steps. First, running or spring water is supplied, to which optionally a conductivity salt such as sodium chloride (NaCl) is added at a concentration of 0.5 to 2 g / L.
  • a conductivity salt such as sodium chloride (NaCl) is added at a concentration of 0.5 to 2 g / L.
  • this water is subjected to electrolysis by a device comprising at least one diamond electrode doped with boron fixed on silicon substrate in which the boron concentration is between 200 ppm (3 ⁇ 10 19 B atoms / cm 3 ) and 1500 ppm (2x10 20 B atoms / cm 3 ), the said module subjecting the water to a quantity of the current during the electrolysis process of between 15 and 500 mAh / L of water, more preferably 40 to 250 mAh / L of water, even more preferably 50 to 200 mAh / L, the electrolysis time being between 15 and 60 minutes.
  • this electrolysis can be carried out cyclically and the number of cycles is between 2 to 12 times over a 24 hour period and spaced at least half an hour. In the case of a fairly small amount of water used, it can be subjected to a single electrolysis for the period mentioned and between 15 and 30 minutes in the case of unitary or single use.
  • An object of the said invention is therefore water as a product obtained by the obtaining process.
  • the water thus obtained by the electrolysis process of the invention is suitable for use in the treatment of inflammatory skin diseases and more particularly for use in the treatment of eczema or atopic dermatitis.
  • the water thus obtained can be used in different forms or compositions or within different devices.
  • the devices used can be selected from a swimming pool, a spa, a bathtub or a water distribution system such as a tap or a shower or an appropriate ambulatory treatment device.
  • the electrolysis module used will then be integrated into an existing water circuit in order to prepare the electrolyzed water, for example in swimming pools or spas, or added and connected as a mobile device on a hydraulic circuit in connection with a tap if you consider a shower or a bathtub.
  • a electrolysis device and a water tank of determined volume can be connected or assembled in a closed circuit with an applicator member or tap, a recovery device can also be combined so as to avoid losses to the water sewer electrolysed treatment and its recycling to the tank for a new electrolysis.
  • the initial water subjected to electrolysis whatever its source, is purified and potentiated by electrolysis. It is therefore not necessary to use distilled water, the electrolysis process of the invention providing an effect as a natural anti-bacterial and fungicide, making it possible to obtain quality water.
  • any water whether natural, spring or municipal water can be used in the process for obtaining the electrolyzed water according to the invention.
  • the advantage and flexibility of use of the electrolysis module according to the invention makes it possible to obtain, from a common water source, a less expensive treatment since it does not require conventional chemicals in the treatment of inflammatory diseases of the skin, while avoiding the side effects of said chemicals.
  • the advantage is that a large area can be treated; it can affect the whole body or all or parts of the body, especially effective when the inflammatory disease is localized in different areas; this avoids using large amounts of cream.
  • the treatment can be carried out in a bath for an exposure period ranging from 5 to 45 minutes and repeated more than once a day until the inflammatory symptoms disappear or improve.
  • the treatment is more effective after two days and from 5 hours after exposure for fifteen minutes in a bath comprising the electrolysed water according to the method of the invention.
  • a very high density of inflammation of the skin is observed in the foot, which subsides 5 hours after exposure in the bath, then two days after the bath, the inflammatory part appears be in the form of a crust still reddish but no longer causing itching conducive to forming crusts which will fade later.
  • the electrolyzed water obtained by the process according to the invention, can also be present in more conventional compositions which are encountered on sale in pharmacies or parapharmacies or even large areas, said composition comprising 95 to 100% of electrolyzed water and 0 to 5% of an excipient and / or emulsifier.
  • composition for use as a medicament in the treatment of inflammatory skin diseases more particularly eczema or atopic dermatitis.
  • It can be in the form of a cream, gel, dressing, patch.
  • the excipients and / or natural or synthetic emulsifiers selected from petrolatum, glycerin, paraffin, cetearyl glucose, beeswax or rice wax, soya lecithin, esters of sugar, glyceryl stearate, olive oil derivatives or a mixture of these.
  • Another galenical form which can be used of the composition according to the invention for treating skin conditions can consist of a mask which can be applied to the skin or the face, said mask being obtained from a powder such as a clay, an exfoliant. , a plant extract in powder or a clay containing activated carbon and added with electrolyzed water obtained according to the process described above.
  • a person skilled in the art will know how to adapt the ratio between powder and electrolyzed water according to the invention in order to obtain the consistency of the mask desired.
  • oil in water also called O / W
  • the amount of water is greater than the amount of oil.
  • This type of emulsion is nourishing and hydrating. It is ideally used to make day creams, body milks, it can also be integrated into patches or adhesives of the dressing type.
  • a hydrogel is a gel in which the blowing agent is water.
  • the matrix of a hydrogel is generally a network of polymers which are insoluble in water, but are capable of swelling substantially in the presence of a large amount of water or aqueous solutions.
  • compositions according to the invention may be possible depending on the needs of the patient to be treated and the extent of the inflammation process. It can be in the form of a cream, gel or emulsion or in the form of a dressing-type adhesive or a skin patch.
  • the composition according to the invention in the case of a composition called O / W (oil in water) comprises from 95 to 100% of electrolyzed water and from 0 to 5% of an excipient and / or emulsifier.
  • the electrolyzed water is not the majority compound; this is the case of a composition called W / O (water in oil), said composition comprises from 70 to 90% of an excipient and / or emulsifier from 10 to 30% by weight of electrolysed water.
  • a hydrogel is a gel in which the blowing agent is water.
  • the matrix of a hydrogel is generally a network of polymers which are insoluble in water, but are capable of swelling substantially in the presence of a large amount of water or aqueous solutions.
  • the boron-doped electrodes (hereinafter designated BDD / Si electrodes) used in this experiment have the following characteristics:
  • BDD / Si electrodes diamond film doped with boron on silicon substrate: Substrate: monocrystalline silicon (100), resistivity 100 mohm.cm
  • - BDD film polycrystalline, thickness ⁇ 2-3pm, doping 1200 ppm of boron (Electrode A) or 2500 ppm of boron (Electrode B),
  • the electrodes A and B were manufactured according to the same diamond film growth protocol in an HF-CVD machine (Hot Filament Chemical Vapor Deposition. They are identical in all respects and differ only in their respective boron content.
  • HF-CVD machine Hot Filament Chemical Vapor Deposition. They are identical in all respects and differ only in their respective boron content.
  • the protocol of implementation of the electrodes on the culture water is as follows:
  • a 2.5 L tank contains city water at 15 ° C. This water is pumped at a fixed flow rate of 200 L / h through an electrolysis module and then returned to the tank, therefore in a closed circuit.
  • the electrolysis module implements 2 electrodes spaced 1 mm and 70 cm 2 of active surface.
  • the water in the tank is kept at a constant temperature of 20 ° C during the test.
  • the culture protocol is as follows:
  • Fibroblasts L-929 (mouse fibroblasts; ACC 173; DSMZ); internal passage P52-53; recommended according to EN ISO 10993-5: 2009).
  • the cells are incubated and cultured en masse in an incubator at 37 ° C with a controlled closed environment containing 5% CO 2 and 95% air.
  • the culture medium is RPMI 1640 with 10% physiological bovine serum, 100 Unit / ml of penicillin and 100 ⁇ g / ml of streptomycin.
  • the protocol for studying cell regeneration / healing is as follows:
  • silicone culture inserts ibidi GmbH, Oberkoch.
  • this insert When this insert is placed in a culture medium, it constitutes 2 culture tanks separated by a wall 500 ⁇ m thick. The cells are cultured in the two tanks and the silicone insert is removed. This makes it possible to obtain two perfectly defined culture patches spaced precisely 500 ⁇ m apart.
  • cells type L-929 were obtained from 80 to 90% by mass of suspension cultures with a density of 500,000 cells / ml. 100 ⁇ L of suspension are introduced into each culture insert reservoir. The cells are cultured for 24 hours in order to obtain homogeneous populations in each of the two reservoirs of each insert. Then, the insert is gently removed, revealing a free space of 500 ⁇ m separating the two culture media. The electrolyzed water is injected up to 500 pL for 1.500 pL of fresh culture medium (dilution 1: 4). The culture media are cultured again for 24 hours. Then, layers of cells were fixed by methanol treatment for 2 min and colored with a Coomassie-Giemsa solution according to Romanowsky.
  • the protocol for tap water electrolysis is as follows:
  • the water used is city water.
  • the electrolysis protocol is as follows: City water is pumped at a flow rate of 90 L / h through an electrolysis module equipped with 2 BDD A electrodes as defined in Example 1 (1200 ppm B) spaced 1 mm apart, having 12.5 cm 2 of active surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental & Geological Engineering (AREA)
  • Hydrology & Water Resources (AREA)
  • Water Supply & Treatment (AREA)
  • Electrochemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Medicinal Preparation (AREA)
EP19813431.4A 2018-11-21 2019-11-21 Behandlung von hautkrankheiten auf der basis von elektrolysiertem wasser Pending EP3883889A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1871657A FR3088543B1 (fr) 2018-11-21 2018-11-21 Traitement des affections de la peau à base d’eau électrolysée
PCT/EP2019/082163 WO2020104630A1 (fr) 2018-11-21 2019-11-21 Traitement des affections de la peau à base d'eau électrolysée

Publications (1)

Publication Number Publication Date
EP3883889A1 true EP3883889A1 (de) 2021-09-29

Family

ID=66641014

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19813431.4A Pending EP3883889A1 (de) 2018-11-21 2019-11-21 Behandlung von hautkrankheiten auf der basis von elektrolysiertem wasser

Country Status (10)

Country Link
US (1) US20210403347A1 (de)
EP (1) EP3883889A1 (de)
JP (1) JP2022507794A (de)
CN (1) CN113316561A (de)
AU (1) AU2019382893A1 (de)
BR (1) BR112021009675A8 (de)
EA (1) EA202191297A1 (de)
FR (1) FR3088543B1 (de)
IL (1) IL283263A (de)
WO (1) WO2020104630A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655163B2 (en) 2020-05-19 2023-05-23 Waterdiam Group Llc Clean water for bathing and medical treatments
FR3140872A1 (fr) * 2022-10-18 2024-04-19 Weo Llc. Bouteille d’eau comprenant un dispositif d’augmentation des fonctions de l’eau

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09268395A (ja) * 1996-04-02 1997-10-14 Permelec Electrode Ltd 電解用電極及び該電極を使用する電解槽
JPH11332944A (ja) * 1998-05-22 1999-12-07 Kazuyuki Kaneko 皮膚炎症の治療法及びその装置
JP4811844B2 (ja) * 2003-11-11 2011-11-09 ペルメレック電極株式会社 過炭酸の製造方法
JP4410155B2 (ja) * 2005-06-16 2010-02-03 ペルメレック電極株式会社 電解水噴出装置
US7927452B2 (en) 2005-07-15 2011-04-19 Toyo Tire & Rubber Co., Ltd. Layered sheets and processes for producing the same
JP4903405B2 (ja) * 2005-08-10 2012-03-28 東海旅客鉄道株式会社 オゾン水生成方法及びオゾン水生成装置
US8147444B2 (en) * 2006-01-20 2012-04-03 Oculus Innovative Sciences, Inc. Methods of treating or preventing peritonitis with oxidative reductive potential water solution
JP5503287B2 (ja) * 2006-09-05 2014-05-28 エレメント シックス リミテッド 固体電極
JP5098050B2 (ja) * 2006-11-16 2012-12-12 ペルメレック電極株式会社 膜−電極接合体、これを用いた電解ユニット、電解水噴出装置及び殺菌方法
PT2162140E (pt) * 2007-04-25 2013-08-27 Apr Nanotechnologies S A Água electrolítica altamente estável com largura reduzida de meia linha da rmn
JP5582711B2 (ja) * 2008-09-25 2014-09-03 株式会社エー・アイ・システムプロダクト ローション状の塗薬
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
FR3000399B1 (fr) 2012-12-31 2015-03-27 Galderma Res & Dev Utilisation topique du laropiprant pour le traitement de la rosacee
AT514092B1 (de) * 2013-02-21 2015-02-15 Pro Aqua Diamantelektroden Produktion Gmbh & Co Kg Verwendung von Elektrolysewasser und Verfahren zum Verhindern bzw. Behindern sowie zur Reduktion von Sporenkeimung und Myzelwachstum von Pilzen der Gattungen Botrytis und Fusarium
FR3051206B1 (fr) * 2016-05-10 2020-06-12 Waterdiam France Dispositif de traitement et de distribution d'eau pour une exploitation agricole
GB2551692B (en) * 2016-05-20 2020-12-09 Ozo Innovations Ltd Electrolyzed water composition
FR3055550B1 (fr) 2016-09-02 2019-06-28 Sigma Clermont Nouvel actif immunomodulateur et composition le comprenant
US20210403348A1 (en) * 2018-02-28 2021-12-30 Waterdiam France Electrolysis method and device for spas and pools

Also Published As

Publication number Publication date
AU2019382893A1 (en) 2021-06-24
CN113316561A (zh) 2021-08-27
FR3088543A1 (fr) 2020-05-22
BR112021009675A8 (pt) 2022-11-29
FR3088543B1 (fr) 2021-03-19
WO2020104630A1 (fr) 2020-05-28
BR112021009675A2 (pt) 2021-08-24
JP2022507794A (ja) 2022-01-18
IL283263A (en) 2021-07-29
EA202191297A1 (ru) 2021-09-10
US20210403347A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
ES2363019T3 (es) Utilización de pirlindol para el tratamiento de las enfermedades que están caracterizadas por una proliferación de los linfocitos t y/o una hiperproliferación de queratinocitos en particular la dermatitis atópica y la psoriasis.
KR20080043763A (ko) 염증성 상태의 치료
FR2847267A1 (fr) Procede de test de l'activite d'une substance potentiellement active pour inhiber l'activite enzymatique de la phospholipase a2
WO2001037799A1 (fr) Extrait d'ajuga turkestanica et ses applications cosmetiques
EP2266530B1 (de) Oxazolidinone für eine kosmetische kutane Verwendung
EP3393488B1 (de) Zusammensetzung mit einem ambora-extrakt und einem grüntee-extrakt zur behandlung von psoriasis, atopischer dermatitis, chronischer urtikaria, antihistaminresistentem pruritus und senilem pruritus
EP3883583B1 (de) Heilende zusammensetzung mit elektrolysiertem wasser
WO2020104630A1 (fr) Traitement des affections de la peau à base d'eau électrolysée
WO2010052312A2 (fr) Médicament ou compostion dermatologique comprenant un extrait peptidique d'avocat destiné au traitement et à la prévention du prurit
EP2986347B1 (de) Kosmetische verwendungen von lactobacillus pentosus
FR3000896A1 (fr) Forme galenique pour l'administration de principe(s) actif(s) permettant l'induction acceleree du sommeil et/ou le traitement des troubles du sommeil
Gadzhigoroeva et al. COVID-19 can exacerbate pattern hair loss and trigger telogen effluvium-the role of proteoglycan replacement therapy with nourkrin® in clinical treatment of covid-19 associated hair loss
EP1458347B1 (de) Mindestens ein alkanolamid enthaltende zusammensetzung zur inhibierung der migration der langerhanszellen und deren verwendung
WO2019092264A1 (fr) Utilisation du 4-(1-phényléthyl)benzène-1,3-diol dans le traitement des dermatoses inflammatoires
EP3946378A1 (de) Dextransulfat für entzündliche hautkrankheiten
RU2571072C1 (ru) Средство для лечения и профилактики зудящих дерматозов
JP7396585B2 (ja) Tslp遺伝子発現抑制用、il-33遺伝子発現抑制用、又はフィラグリン産生促進用組成物
JP2005298504A (ja) 混合異性化糖及び銀杏葉抽出物を含有する皮膚外用剤組成物
WO2023180981A1 (fr) Extrait de melaleuca alternifolia et ses utilisations cosmétiques
EP3766505B1 (de) Behandlung von hautläsionen in verbindung mit autoimmunkrankheiten und entzündlichen erkrankungen mit der arsenverbindung as2o5
WO2019063929A1 (fr) Utilisation cosmetique de cellules meristematiques de syringa vulgaris l. pour une action apaisante et/ou adoucissante sur la peau
BE1027772A1 (fr) Composition de ginseng pour ameliorer l'etat de la peau et son utilisation pour le traitement d'une maladie dermatologique
FR3088824A1 (fr) Fucanes sulfates de bas poids moleculaire dans les dermatoses inflammatoires
FR3065372A1 (fr) Composition comprenant de la carboxy methyl naringenine chalcone pour le traitement du prurit et de la dermatite atopique
FR3065373A1 (fr) Composition comprenant un extrait de cognassier pour le traitement du prurit et de la dermatite atopique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WEO, LLC

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230515

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240125